Document is current
Any future updates will be listed below
-
Authors
Jouvenel, Antoine
Tassou, Adrien https://orcid.org/0000-0003-2148-553X
Thouaye, Maxime
Ruel, Jérôme
Antri, Myriam
Leyris, Jean-Philippe
Giraudin, Aurore
Mallié, Sylvie
Sar, Chamroeum
Diouloufet, Lucie
Sonrier, Corinne
Daubeuf, François https://orcid.org/0000-0001-8061-5897
Bertin, Juliette
Alves, Stacy
Ventéo, Stéphanie
Frossard, Nelly
Carroll, Patrick
Mechaly, Ilana
Rognan, Didier https://orcid.org/0000-0002-0577-641X
Sokoloff, Pierre https://orcid.org/0000-0002-7129-6043
Dallel, Radhouane
Delmas, Patrick https://orcid.org/0000-0002-0123-5413
Valmier, Jean https://orcid.org/0000-0002-2748-9104
Rivat, Cyril https://orcid.org/0000-0002-7491-6113
-
Funding
Funding for this research was provided by:
ANR
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 30 October 2024
First Online: 7 November 2024
Competing interests
: C.S., L.D., J.B., and J.P.L. were full-time employees at Biodol Therapeutics. J.V. is inventor of patents (WO2011/083124, WO2016/016370, WO2017211937, EP2023/0779572023) claiming the use of FLT3 inhibitors for the treatment of neuropathic pain and is co-founder of Biodol Therapeutics with P.S. and D.R. The other authors declare no conflict of interests related to the current investigation.
